Trial Profile
A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Carboplatin; Cisplatin; Dexamethasone; Folic acid; Vitamin B12 analogues
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-189
- Sponsors Merck Sharp & Dohme Corp.
- 24 Jan 2024 This trial has been completed in Germany, according to the European Clinical Trials Database record.
- 12 Sep 2023 Results of pooled analysis of 5-year outcomes , from KEYNOTE-407 China Extension, KEYNOTE-407, KEYNOTE-189 and KEYNOTE-189 Japan extension presented at the 24th World Conference on Lung Cancer
- 23 Jul 2023 This trial has been completed in Netherlands (Date of the global end of the trial: 22-Jun-2023), according to the European Clinical Trials Database record.